Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 09 September 2025 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees.

Implantica AG (publ.), ett medicintekniskt företag som ligger i framkant när det gäller att introducera avancerad teknik i kroppen, meddelar att bolaget den 09 september 2025 genomförde en riktad nyemission av aktier utan betalning för att tillgodose delar av aktieincitamentsprogrammet för nyckelpersoner.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces its strategy to produce 10,000 RefluxStop® devices in preparation for the expected, substantial demand from the U.S. market, following FDA PMA approval.

Implantica AG (publ), ett medicintekniskt företag som ligger i framkant när det gäller att introducera avancerad teknik i kroppen, inklusive den unika produkten RefluxStop™ för behandling av sura uppstötningar, ett behandlingsområde med 1 miljard drabbade, tillkännager sin strategi att tillverka 10 000 RefluxStop®-enheter som förberedelse för den förväntade stora efterfrågan från den amerikanska marknaden efter FDA:s PMA-godkännande.

Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces completion and initial validation of a new RefluxStop® U.S. production tool as Implantica prepares for quickly increasing demand from the U.S. and markets worldwide, pending FDA approval.

Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the second quarter will be published at 8:00 a.m. CEST on the same day.

Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed publication of the remarkable 5-year outcomes from its CE mark clinical study of RefluxStop®, a revolutionary device for the treatment of acid reflux—a condition affecting over 1 billion people worldwide.

Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop’s extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy (https://link.springer.com/article/10.1007/s00464-025-11818-x), an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery).

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module.